Germany has become the first EU country to allow legal access to psilocybin under a compassionate use program for treatment-resistant depression. Unlike other countries’ pre-approval pathways, Germany’s model empowers clinicians to decide on patient eligibility without case-by-case regulatory approval and might succeed in having insurers cover much of the cost. Here, we speak with one of the program’s key architects, Gerhard Gründer.